January 23, 2026

How cells control inflammatory responses

How cells control inflammatory responses

Inflammation has to work fast against pathogens—but it can’t get out of control. Researchers at the German Cancer Research Center (DKFZ) have now deciphered in more detail how the organism masters this balancing act. Their work shows that cells use two different strategies to precisely control inflammatory genes and thus precisely regulate the inflammatory response.

The fluorescence microscope image shows TNF-induced expression of the inflammatory genes CXCL1 (cyan), CXCL2 (yellow), and CXCL8 (purple) in human cells (together with protein markers).

Inflammation plays a central role in defending against pathogens, repairing tissue, and healing wounds. A large number of genes are involved in an inflammatory response. They ensure that cytokines are released, immune cells are activated, and blood vessels become more permeable. The activation of these genes, which is largely controlled by tumor necrosis factor (TNF), is a constant balancing act for the cell: if it is too weak, the body cannot effectively fight infections. If activation is too strong or lasts too long, there is a risk of chronic inflammation, tissue damage, autoimmune diseases, or cancer. This makes it all the more important for cells to regulate inflammatory genes at exactly the right time and to the right degree.

Researchers at the German Cancer Research Center (DKFZ) and Heidelberg University have now shown that cells use two different strategies for this purpose, which they also combine. Using human vascular cells, the team was able to trace how around 1,500 different TNF-induced inflammatory genes are switched on in a controlled manner after an inflammatory stimulus.

Some of these genes are regulated via loose, short-lived contacts in the genome. A kind of DNA loop formation temporarily brings the target gene to be activated and distant regulatory DNA segments together spatially. These contacts are not stable and quickly dissolve again. They enable finely tuned and flexible control of individual genes, especially those that are activated later or only in some of the cells.

In addition, the Heidelberg team identified control centers in the cell nucleus. In these areas, many regulatory proteins, known as transcription factors, dock close together on the DNA. The inflammatory genes are often located in clusters and are activated together. Such control centers allow for rapid, strong, and coordinated activation of genes—ideal for a rapid inflammatory response when the body needs to react immediately.

“Inflammation is not switched on and off like a toggle switch, but is a finely modulated process,” says study leader Karsten Rippe from the DKFZ. “Through the interaction of both mechanisms, the cell can precisely initiate, amplify, and later dampen inflammatory responses. The switching centers enable a rapid initial response, while the loose contacts ensure targeted fine-tuning as the process continues.”

The results provide an important basis for better understanding misdirected inflammatory processes—for example, in chronic inflammatory diseases or cancer—and possibly developing more targeted therapeutic approaches in the long term.


Isabelle Seufert, Irene Gerosa, Vassiliki Varamogianni-Mamatsi, Anastasiya Vladimirova, Ezgi Sen, Stefanie Mantz, Anne Rademacher, Sabrina Schumacher, Panagiotis Liakopoulos, Petros Kolovos, Simon Anders, Jan-Philipp Mallm, Argyris Papantonis & Karsten Rippe: Two distinct chromatin modules regulate proinflammatory gene expression
Nature Cell Biology 2025, https://doi.org/10.1038/s41556-025-01819-2

Our latest News

discover more
China’s NMPA approves Promega’s MSI detection kit as a companion diagnostic for KEYTRUDA®

China’s NMPA approves Promega’s MSI detection kit as a companion diagnostic for KEYTRUDA®

The National Medical Products Administration (NMPA) in China has approved the OncoMate® Microsatellite Instability (MSI) Detection Kit as a Class III in vitro diagnostic device in China. It is intended as a companion diagnostic to identify patients with MSI-high (MSI-H) solid tumors for treatment with KEYTRUDA® (pembrolizumab), the anti-PD-1 therapy from Merck & Co., Inc., […]

aimed analytics GmbH highlighted in deutsche-startups.de

aimed analytics GmbH highlighted in deutsche-startups.de

5 neue Startups: ONOX, aimed analytics, Recarbox, FORMIC, showroom.fm Es ist wieder soweit – neue Startups stehen in den Startlöchern! Hier sind einige spannende junge Unternehmen, die man kennen sollte. Heute werfen wir einen Blick auf diese Neugründungen: ONOX, aimed analytics, Recarbox, FORMIC und showroom.fm. deutsche-startups.de stellt heute erneut eine Auswahl junger Startups vor, die […]

BioMed X Launches First Research Project in Partnership with the Government of Barbados to Advance Therapy of Early Diabetic Kidney Disease

BioMed X Launches First Research Project in Partnership with the Government of Barbados to Advance Therapy of Early Diabetic Kidney Disease

Bridgetown, Barbados, January 27, 2026 – BioMed X, a leading innovation hub for pharma, today announced the launch of its first research project in partnership with the Government of Barbados and with support from the European Union’s PharmaNext Programme. The new global call for research proposals, entitled “AI-Enabled Therapy of Early Diabetic Kidney Disease in Barbados,” addresses one of the most pressing and underexplored […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp